An observational cohort study assessing durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naive HIV-infected patients starting antiretroviral therapy
Latest Information Update: 12 Jan 2022
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary) ; Cobicistat/elvitegravir/emtricitabine/tenofovir (Primary) ; Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary) ; Emtricitabine/rilpivirine/tenofovir alafenamide (Primary) ; Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary) ; Raltegravir (Primary)
- Indications HIV infections
- Focus Therapeutic Use
Most Recent Events
- 12 Jan 2022 New trial record